A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 810 participants.
Also called NCT01075282
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 810 participants
- Sponsor
- Registry
-
NCT01075282
-
- Other papers using this trial's data
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Belgium, Brazil, Canada, Croatia, Czechia, France, Greece, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01075282. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2015-01-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
- Acronym
- AWARD-2
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- LY2189265
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01075282- Content hash
e7c3690e99c0d9a10097589a0394c7f1b690390117fc44691813c7dc6e257220